• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by ABIOMED Inc.

    12/22/22 4:40:54 PM ET
    $ABMD
    Medical/Dental Instruments
    Health Care
    Get the next $ABMD alert in real time by email
    S-8 POS 1 d409517ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission December 22, 2022

    Registration No. 33-23053

    Registration No. 33-38030

    Registration No. 33-65192

    Registration No. 333-38865

    Registration No. 333-66029

    Registration No. 333-103245

    Registration No. 333-114066

    Registration No. 333-123675

    Registration No. 333-123676

    Registration No. 333-132054

    Registration No. 333-152989

    Registration No. 333-176620

    Registration No. 333-186613

    Registration No. 333-206395

    Registration No. 333-209414

    Registration No. 333-213319

    Registration No. 333-227226

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    Post-Effective Amendment No. 3 to Form S-8 Registration Statement No. 33-23053

    Post-Effective Amendment No. 2 to Form S-8 Registration Statement No. 33-38030

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 33-65192

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-38865

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-66029

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-103245

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-114066

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-123675

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-123676

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-132054

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-152989

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-176620

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-186613

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-206395

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-209414

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-213319

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-227226

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    LOGO

    ABIOMED, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   04-2743260
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

    22 Cherry Hill Drive

    Danvers, Massachusetts 01923

    (503) 331-7270

    (Address, including Zip Code, and Telephone Number, including Area Code, of Registrant’s Principal Executive Offices)

    ABIOMED, Inc. Incentive Stock Option Plan

    ABIOMED, Inc. Non-Qualified Stock Option Plan

    ABIOMED, Inc. 1992 Combination Stock Option Plan

    ABIOMED, Inc. 1989 Non-Qualified Stock Option Plan for Non-Employee Directors

    ABIOMED, Inc. 1988 Employee Stock Purchase Plan

    ABIOMED, Inc. 1998 Equity Incentive Plan

    ABIOMED, Inc. 2000 Stock Incentive Plan

    Nonqualified Stock Option Granted by ABIOMED, Inc. to Michael R. Minogue Dated April 5, 2004

    ABIOMED Retirement Savings Plan

    ABIOMED, Inc. 2008 Stock Incentive Plan

    ABIOMED, Inc. Amended and Restated 2008 Stock Incentive Plan

    ABIOMED, Inc. Second Amended and Restated 2008 Stock Incentive Plan

    ABIOMED, Inc. 2015 Omnibus Incentive Plan

    ABIOMED, Inc. Fourth Amended and Restated 2008 Stock Incentive Plan

    ABIOMED, Inc. Amended & Restated 2015 Omnibus Incentive Plan

    ABIOMED, Inc. Second Amended & Restated 2015 Omnibus Incentive Plan

    (Full Title of the Plans)

    Michael R. Minogue

    Chairman, President and Chief Executive Officer

    ABIOMED, Inc.

    22 Cherry Hill Drive

    Danvers Massachusetts 01923

    (Name and Address, including Zip Code, of Agent for Service)

     

     

    with copies to:

     

    Matthew G. Hurd

    Sullivan & Cromwell LLP

    125 Broad Street

    New York, New York 10004

    (212) 558-3122

     

    Robert W. Downes

    Sullivan & Cromwell LLP

    125 Broad Street

    New York, New York 10004

    (212) 558-4312

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☒
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     


    EXPLANATORY NOTE

    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment relates to the following Registration Statements on Form S-8 (each, a “Registration Statement,” and collectively, the “Registration Statements”) previously filed by ABIOMED, Inc., a Delaware Corporation (the “Company”), with the U.S. Securities and Exchange Commission (the “SEC”):

     

      •  

    Registration Statement on Form S-8 (File No. 33-23053), originally filed with the SEC on July 11, 1988, registering 700,000 shares of the Company’s common stock, par value $0.01 per share (“Shares”), issuable in connection with the Company’s Incentive Stock Option Plan, Non-Qualified Stock Option Plan and 1988 Employee Stock Purchase Plan, at a proposed maximum offering price per share of $9.125. (P)

     

      •  

    Registration Statement on Form S-8 (File No. 33-38030), which incorporates by reference and serves as Post-Effective Amendment No.1 to Registration Statement No. 33-23053 on Form S-8, originally filed with the SEC on November 30, 1990, registering 350,000 Shares issuable in connection with the Company’s Incentive Stock Option Plan, Non-Qualified Stock Option Plan, 1989 Non-Qualified Stock Option Plan for Non-Employee Directors and 1988 Employee Stock Purchase Plan, at a proposed maximum offering price per share of $5.625. (P)

     

      •  

    Registration Statement on Form S-8 (File No. 33-65192), which incorporates by reference and serves as Post-Effective Amendment No. 2 to Registration Statement No. 33-23053 on Form S-8 and Post-Effective Amendment No. 1 to Registration Statement No. 33-38030 on Form S-8, originally filed with the SEC on June 28, 1993, registering 250,000 Shares issuable in connection with the Company’s 1992 Combination Stock Option Plan (formerly known as (1) the Incentive Stock Option Plan and (2) the Non-Qualified Stock Option Plan), at a proposed maximum offering price per share of $8.25. (P)

     

      •  

    Registration Statement on Form S-8 (File No. 333-38865), originally filed with the SEC on October  28, 1997, registering (i) 1,850,000 preferred share purchase rights (“Rights”) issuable in connection with the Company’s 1992 Combination Stock Option Plan, 1989 Non-Qualified Stock Option Plan for Non-Employee Directors and 1988 Employee Stock Purchase Plan; (ii) 500,000 Shares issuable in connection with the Company’s 1992 Combination Stock Option Plan; and (iii) 50,000 Shares issuable in connection the Company’s 1989 Non-Qualified Stock Option Plan for Non-Employee Directors, at a proposed maximum offering price per share of $21.00.

     

      •  

    Registration Statement on Form S-8 (File No. 333-66029), originally filed with the SEC on October  23, 1998, registering (i) 500,000 Rights issuable in connection with the Company’s 1998 Equity Incentive Plan and (ii) 500,000 Shares issuable in connection with the Company’s 1998 Equity Incentive Plan, at a proposed maximum offering price per share of $9.157.

     

      •  

    Registration Statement on Form S-8 (File No. 333-103245), originally filed with the SEC on February 14, 2003, registering 1,400,000 Shares issuable in connection with the Company’s 2000 Stock Incentive Plan, at a proposed maximum offering price per share of $3.99.

     

      •  

    Registration Statement on Form S-8 (File No. 333-114066), originally filed with the SEC on March 31, 2004, registering (i) 1,500,000 Shares issuable in connection with the Company’s 2000 Stock Incentive Plan and (ii) 300,000 Shares issuable in connection with the Company’s 1988 Employee Stock Purchase Plan, at a proposed maximum offering price per share of $7.96.

     

      •  

    Registration Statement on Form S-8 (File No. 333-123675), originally filed with the SEC on March 30, 2005, registering a grant of 100,000 Shares issuable pursuant to Non-Qualified Stock Option granted by the Company to Michael R. Minogue, Chief Executive Officer and President, at a proposed maximum offering price per share of $9.05.

     

    -2-


      •  

    Registration Statement on Form S-8 (File No. 333-123676), originally filed with the SEC on March 30, 2005, registering 750,000 Shares under the Company’s Retirement Savings Plan, at a proposed maximum offering price per share of $10.29.

     

      •  

    Registration Statement on Form S-8 (File No. 333-132054), originally filed with the SEC on February 27, 2006, registering 2,000,000 Shares issuable in connection with the Company’s 2000 Stock Incentive Plan, at a proposed maximum offering price per share of $10.63.

     

      •  

    Registration Statement on Form S-8 (File No. 333-152989), originally filed with the SEC on August 13, 2008, registering 2,000,000 Shares issuable in connection with the Company’s 2008 Stock Incentive Plan, at a proposed maximum offering price per share of $19.08.

     

      •  

    Registration Statement on Form S-8 (File No. 333-176620), originally filed with the SEC on September 1, 2011, registering 3,200,000 Shares issuable in connection with the Company’s Amended and Restated 2008 Stock Incentive Plan, at a proposed maximum offering price per share of $11.36.

     

      •  

    Registration Statement on Form S-8 (File No. 333-186613), originally filed with the SEC on February 12, 2013, registering (i) 1,000,000 Shares issuable in connection with the Company’s Second Amended and Restated 2008 Stock Incentive Plan and (ii) 350,000 Shares issuable in connection with the Company’s 1988 Employee Stock Purchase Plan, at a proposed maximum offering price per share of $13.38.

     

      •  

    Registration Statement on Form S-8 (File No. 333-206395), originally filed with the SEC on August 14, 2015, registering 2,000,000 Shares issuable in connection with the Company’s 2015 Omnibus Incentive Plan, at a proposed maximum offering price per share of $97.63.

     

      •  

    Registration Statement on Form S-8 (File No. 333-209414), originally filed with the SEC on February 5 2016, registering 1,700,000 Shares issuable in connection with the Company’s Fourth Amended and Restated 2008 Stock Incentive Plan, at a proposed maximum offering price per share of $85.29.

     

      •  

    Registration Statement on Form S-8 (File No. 333-213319), originally filed with the SEC on August 25, 2016, registering 1,260,000 Shares issuable in connection with the Company’s Amended & Restated 2015 Omnibus Incentive Plan, at a proposed maximum offering price per share of $119.48.

     

      •  

    Registration Statement on Form S-8 (File No. 333-227226), originally filed with the SEC on September 7, 2018, registering 1,725,000 Shares issuable in connection with the Company’s Second Amended & Restated 2015 Omnibus Incentive Plan, at a proposed maximum offering price per share of $397.06.

    This Post-Effective Amendment is being filed in connection with the closing on December 22, 2022 of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of October 31, 2022 (the “Merger Agreement”), by and among Johnson & Johnson, a New Jersey corporation (“Parent”), Athos Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the Company. On December 22, 2022, pursuant to the Merger Agreement, Merger Sub was merged with and into the Company (the “Merger”), with the Company surviving the Merger and continuing as a wholly owned subsidiary of Parent.

    As a result of the Merger, the Company has terminated all offerings of the Company’s securities pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statements. In accordance with undertakings made by the Company in the Registration Statements to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance that remain unsold at the termination of the offering, the Company hereby removes from registration all such securities of the Company registered pursuant to the Registration Statements that remain unsold and any plan interests that are unissued as of the date hereof. Each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities.

     

    -3-


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Danvers, Commonwealth of Massachusetts, on December 22, 2022. No other person is required to sign this Post-Effective Amendment to the Registration Statements in reliance upon Rule 478 under the Securities Act of 1933, as amended.

     

    ABIOMED, Inc.
    By:  

    /s/ Andrew Greenfield

      Name:   Andrew Greenfield
      Title:   Executive Vice President, Chief Commercial Officer

     

    -4-

    Get the next $ABMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABMD

    DatePrice TargetRatingAnalyst
    11/2/2022$235.00 → $380.00Underweight → Equal-Weight
    Morgan Stanley
    11/2/2022$355.00 → $388.00Buy → Hold
    Deutsche Bank
    10/13/2022$300.00Buy
    Mizuho
    4/6/2022$330.00Peer Perform
    Wolfe Research
    2/4/2022$292.00 → $275.00Underweight
    Morgan Stanley
    2/4/2022$345.00 → $325.00Market Perform
    SVB Leerink
    1/7/2022$269.00 → $292.00Underweight
    Morgan Stanley
    8/6/2021$335.00 → $375.00Market Perform
    SVB Leerink
    More analyst ratings

    $ABMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical

      Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja

      7/12/23 9:00:00 AM ET
      $STIM
      $ABMD
      Medical/Dental Instruments
      Health Care
    • FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial

      Abiomed (NASDAQ:ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support at Ascension St. John Hospital in Detroit, led the procedures. This single-arm, prospective, multi-center trial will evaluate the rate of major adverse cardiovascular and cerebrovascular events (MACCE) in adult patients who receive Impella ECP support during an elective or urgent high-risk percutaneous coronary intervention (PCI). This press release features multimedia. View the full release here: htt

      12/21/22 9:00:00 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400

      NEW YORK, Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent Steel Dynamics Inc. (NASD:STLD) will replace Abiomed Inc. (NASD:ABMD) in the S&P 500 and Super Micro Computer Inc. (NASD:SMCI) will replace Steel Dynamics in the S&P MidCap 400 effective prior to the opening of trading on Thursday, December 22. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Abiomed in a deal expected to close soon pending final conditions.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name  Action Company Name Ticker GICS Sector December 22, 2022 S&P 500 Addition Steel Dynamics STLD Materials S&P 500 Deletion

      12/19/22 6:35:00 PM ET
      $ABMD
      $JNJ
      $SMCI
      $SPGI
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Computer Manufacturing

    $ABMD
    SEC Filings

    See more
    • SEC Form 15-12G filed by ABIOMED Inc.

      15-12G - ABIOMED INC (0000815094) (Filer)

      1/3/23 8:30:58 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by ABIOMED Inc.

      S-8 POS - ABIOMED INC (0000815094) (Filer)

      12/22/22 4:46:31 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by ABIOMED Inc.

      S-8 POS - ABIOMED INC (0000815094) (Filer)

      12/22/22 4:46:02 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care

    $ABMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical

      Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja

      7/12/23 9:00:00 AM ET
      $STIM
      $ABMD
      Medical/Dental Instruments
      Health Care
    • MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson

      Succeeds Derek Herrera after two-year term Patrice Sutherland, enterprise executive director at Integra Life Sciences, has been appointed Chairperson of the Board of Directors for MedTechVets, a nonprofit organization that helps military Veterans transition and gain employment at Medical Technology and Life Science companies. This announcement is being made today during the Plenary Luncheon at AdvaMed's MedTech Conference 2022, which is taking place through Oct. 26 at the Boston Convention and Exhibition Center. A U.S. Army combat Veteran, Sutherland succeeds Derek Herrera and will assume the role on January 1, 2023. This press release features multimedia. View the full release here: https

      10/24/22 12:00:00 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • Dr. Paula A. Johnson Joins Abiomed Board of Directors

      Abiomed (NASDAQ:ABMD) announces the appointment of Paula A. Johnson, MD, MPH, to the Abiomed Board of Directors, effective immediately. Dr. Johnson will serve as a member of the Governance and Nominating Committee of the board. Following the appointment of Dr. Johnson, the board now comprises nine active directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005332/en/Dr. Paula A. Johnson joins the Abiomed Board of Directors (Photo: Business Wire) "Dr. Johnson is known internationally as a leading expert in healthcare, medical research and health policy, especially for her work advancing the health of women," said Michae

      4/28/21 8:03:00 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care

    $ABMD
    Financials

    Live finance-specific insights

    See more
    • Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year

      ABIOMED, Inc. (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended September 30, 2022. Second Quarter 2023 Financial Highlights: Revenue of $266 million, an increase of 11% in constant currency, or 7% on a reported basis. This represents Abiomed's 7th consecutive quarter of double-digit constant currency growth. Worldwide product revenue of $253 million, an increase of 11% in constant currency, or 7% on a reported basis. Within the quarter, procedural volumes were impacted in July due to extended physician vacations, coupled with ongoing hospital labor shortages. The company saw an improvement in pa

      11/1/22 7:00:00 AM ET
      $ABMD
      $JNJ
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Johnson & Johnson to Acquire Abiomed

      Strengthens Johnson & Johnson's MedTech Business with the Addition of Abiomed, a World-Leader in Heart Recovery Transaction to Bring Lifesaving Innovations to More Patients with Unmet Need Expected to Enhance Johnson & Johnson's Near- and Long-Term Sales and Earnings Growth; Accretive to Adjusted Earnings beginning in 2024 Conference Call at 8:00 a.m. ET To Discuss Details of the Transaction Johnson & Johnson (NYSE:JNJ), the world's largest, most diversified healthcare products company, and Abiomed (NASDAQ:ABMD), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson wil

      11/1/22 6:30:00 AM ET
      $ABMD
      $JNJ
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification

      Abiomed, Inc. (NASDAQ:ABMD) announced that on Tuesday, November 1, 2022, the Company will release financial results for the second quarter of the fiscal year 2023. The Company will host a conference call to discuss the results on Tuesday, November 1, 2022 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call. To listen to the call live, please tune into the webcast via https://events.q4inc.com/attendee/493387843 or dial (844) 200-6205; the international number is (929) 526-1599 access code 367357. A replay of this conference call will be available until Tuesday, November 8, 2022. The repla

      10/13/22 7:00:00 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care

    $ABMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ABIOMED Inc. (Amendment)

      SC 13G/A - ABIOMED INC (0000815094) (Subject)

      1/6/23 6:39:54 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by ABIOMED Inc.

      SC 13G - ABIOMED INC (0000815094) (Subject)

      12/29/22 4:03:01 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by ABIOMED Inc. (Amendment)

      SC 13G/A - ABIOMED INC (0000815094) (Subject)

      2/9/22 3:16:00 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care

    $ABMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Abiomed upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Abiomed from Underweight to Equal-Weight and set a new price target of $380.00 from $235.00 previously

      11/2/22 9:11:07 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • Abiomed downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Abiomed from Buy to Hold and set a new price target of $388.00 from $355.00 previously

      11/2/22 6:09:28 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • Mizuho initiated coverage on Abiomed with a new price target

      Mizuho initiated coverage of Abiomed with a rating of Buy and set a new price target of $300.00

      10/13/22 7:17:59 AM ET
      $ABMD
      Medical/Dental Instruments
      Health Care

    $ABMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Sutter Martin P returned 123,370 shares to the company, closing all direct ownership in the company

      4 - ABIOMED INC (0000815094) (Issuer)

      12/27/22 8:47:48 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Puhy Dorothy E returned 14,590 shares to the company, closing all direct ownership in the company

      4 - ABIOMED INC (0000815094) (Issuer)

      12/27/22 8:44:35 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Trapp Todd A returned 14,166 shares to the company, closing all direct ownership in the company

      4 - ABIOMED INC (0000815094) (Issuer)

      12/27/22 8:41:11 PM ET
      $ABMD
      Medical/Dental Instruments
      Health Care